Bioinformatics-Driven Oligonucleotide Therapeutics in 2025: Unleashing Precision Medicine and Accelerating Market Growth. Explore How Advanced Analytics and AI Are Transforming Drug Discovery and Delivery Over the Next Five Years.

• Executive Summary: 2025 Market Landscape and Key Drivers
• Bioinformatics Innovations Powering Oligonucleotide Therapeutics
• Current Market Size, Segmentation, and 2025 Forecasts
• Key Players and Strategic Collaborations (e.g., ionispharma.com, alnylam.com, moderna.com)
• AI and Machine Learning in Oligonucleotide Design and Optimization
• Regulatory Environment and Industry Standards (e.g., fda.gov, ema.europa.eu)
• Emerging Therapeutic Applications: Rare Diseases, Oncology, and Beyond
• Manufacturing Advances and Supply Chain Dynamics
• Market Growth Projections: CAGR of 14–17% Through 2030
• Future Outlook: Challenges, Opportunities, and Next-Gen Technologies
• Sources & References

Executive Summary: 2025 Market Landscape and Key Drivers

The market for bioinformatics-driven oligonucleotide therapeutics is poised for significant expansion in 2025, propelled by advances in computational biology, artificial intelligence (AI), and high-throughput sequencing technologies. Oligonucleotide therapeutics—including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers—are increasingly benefiting from bioinformatics platforms that accelerate target identification, optimize sequence design, and predict off-target effects with greater precision. This integration is reducing development timelines and improving the safety and efficacy profiles of novel therapeutics.

Key industry players are leveraging proprietary bioinformatics tools to maintain competitive advantages. Ionis Pharmaceuticals, a pioneer in ASO development, continues to invest in computational platforms for rational drug design, enabling the rapid progression of candidates into clinical trials. Similarly, Alnylam Pharmaceuticals—a leader in RNA interference (RNAi) therapeutics—utilizes advanced in silico modeling to refine siRNA sequences, minimize immunogenicity, and enhance delivery to target tissues. Moderna and Biogen are also expanding their bioinformatics capabilities, particularly in the context of mRNA and oligonucleotide-based therapies for rare and neurodegenerative diseases.

The 2025 landscape is characterized by a surge in partnerships between bioinformatics firms and oligonucleotide drug developers. Companies such as QIAGEN and Illumina are providing next-generation sequencing (NGS) and data analytics platforms that support the discovery and validation of novel targets. These collaborations are expected to intensify as the demand for personalized medicine grows, with bioinformatics playing a central role in patient stratification and biomarker discovery.

Regulatory agencies are also adapting to the evolving landscape. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly recognizing the value of bioinformatics in supporting regulatory submissions, particularly for complex oligonucleotide therapeutics. This is fostering a more favorable environment for innovation and accelerating the approval of new therapies.

Looking ahead, the market outlook for bioinformatics-driven oligonucleotide therapeutics remains robust. The convergence of AI, machine learning, and cloud-based analytics is expected to further streamline drug discovery and development processes. As more oligonucleotide drugs receive regulatory approval and enter the market, the sector is likely to see increased investment, expanded therapeutic indications, and broader adoption of bioinformatics solutions across the pharmaceutical industry.

Bioinformatics Innovations Powering Oligonucleotide Therapeutics

The landscape of oligonucleotide therapeutics is being rapidly transformed by advances in bioinformatics, with 2025 marking a pivotal year for the integration of computational tools into drug discovery and development. Bioinformatics platforms now underpin nearly every stage of oligonucleotide therapeutic design, from target identification and sequence optimization to off-target prediction and delivery system engineering.

A key driver of this transformation is the increasing sophistication of algorithms for predicting RNA secondary structures and interactions, which are critical for the efficacy and safety of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and other nucleic acid-based drugs. Companies such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals—both pioneers in RNA-targeted therapeutics—have invested heavily in proprietary bioinformatics pipelines that enable the rational design of oligonucleotides with improved specificity and reduced immunogenicity. These platforms leverage large-scale genomic and transcriptomic datasets, machine learning, and high-throughput screening data to accelerate candidate selection and de-risk clinical development.

In 2025, the integration of artificial intelligence (AI) and deep learning into bioinformatics workflows is further enhancing the predictive power of these tools. For example, Moderna and Sirnaomics are utilizing AI-driven models to optimize sequence design and delivery vehicles, aiming to improve tissue targeting and minimize off-target effects. These innovations are particularly relevant as the field expands beyond rare genetic diseases into more prevalent indications such as oncology, metabolic disorders, and infectious diseases.

Another significant trend is the emergence of cloud-based bioinformatics platforms that facilitate collaboration and data sharing across the oligonucleotide therapeutics ecosystem. Companies like Thermo Fisher Scientific and Agilent Technologies are providing integrated solutions for oligonucleotide synthesis, analysis, and quality control, streamlining the path from in silico design to clinical-grade manufacturing.

Looking ahead, the next few years are expected to see further convergence of bioinformatics, automation, and synthetic biology, enabling the rapid prototyping and personalized tailoring of oligonucleotide drugs. As regulatory agencies increasingly recognize the value of computational evidence in supporting safety and efficacy claims, bioinformatics-driven approaches are poised to become standard practice in the development of next-generation oligonucleotide therapeutics.

Current Market Size, Segmentation, and 2025 Forecasts

The market for bioinformatics-driven oligonucleotide therapeutics is experiencing robust growth in 2025, propelled by advances in computational biology, high-throughput sequencing, and the increasing clinical validation of oligonucleotide-based drugs. Oligonucleotide therapeutics—including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), aptamers, and CRISPR-based modalities—are increasingly designed and optimized using bioinformatics platforms, which accelerate target identification, sequence optimization, and off-target prediction.

As of 2025, the global oligonucleotide therapeutics market is estimated to be valued in the multi-billion-dollar range, with bioinformatics-driven approaches accounting for a rapidly expanding segment. The market is segmented by therapeutic modality (ASOs, siRNAs, aptamers, and gene editing oligonucleotides), application (rare diseases, oncology, neurology, infectious diseases, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World). North America remains the largest market, driven by a concentration of leading biopharmaceutical companies, advanced research infrastructure, and regulatory support for innovative therapies.

Key industry players are investing heavily in bioinformatics platforms to streamline oligonucleotide drug discovery and development. Ionis Pharmaceuticals, a pioneer in antisense technology, leverages proprietary bioinformatics tools for sequence design and target validation, contributing to its robust pipeline of approved and investigational drugs. Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, utilizes advanced computational methods to optimize siRNA candidates, with several products already on the market and more in late-stage development. Moderna and Biogen are also expanding their oligonucleotide portfolios, integrating bioinformatics to enhance efficacy and safety profiles.

The market is further segmented by the integration of artificial intelligence (AI) and machine learning (ML) in bioinformatics workflows. Companies such as Roche and Thermo Fisher Scientific are developing and supplying bioinformatics software and analytical tools that support oligonucleotide design, synthesis, and quality control, catering to both in-house R&D and contract manufacturing organizations.

Looking ahead, the market is forecasted to maintain double-digit annual growth rates through the next few years, driven by the expanding clinical pipeline, regulatory approvals, and the entry of new players leveraging bioinformatics. The increasing prevalence of rare and genetic diseases, coupled with the demand for precision medicine, is expected to further fuel market expansion. Strategic collaborations between bioinformatics firms and oligonucleotide drug developers are anticipated to accelerate innovation and commercialization, solidifying bioinformatics as a cornerstone of oligonucleotide therapeutics in 2025 and beyond.

Key Players and Strategic Collaborations (e.g., ionispharma.com, alnylam.com, moderna.com)

The landscape of bioinformatics-driven oligonucleotide therapeutics in 2025 is shaped by a dynamic interplay of established leaders, emerging innovators, and strategic collaborations. Key players are leveraging advanced computational platforms to accelerate the discovery, optimization, and clinical translation of oligonucleotide-based drugs, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and messenger RNA (mRNA) therapeutics.

Ionis Pharmaceuticals remains a pioneer in antisense technology, with a robust pipeline spanning rare diseases, neurology, and cardiometabolic disorders. The company’s proprietary bioinformatics tools enable the rational design of ASOs with improved specificity and reduced off-target effects. In 2024–2025, Ionis has expanded its strategic alliances, notably with Novartis and Roche, to co-develop next-generation oligonucleotide therapies targeting neurological and cardiovascular indications. These collaborations integrate Ionis’s oligonucleotide expertise with partners’ clinical and commercial capabilities, aiming to accelerate market entry and broaden therapeutic impact (Ionis Pharmaceuticals).

Alnylam Pharmaceuticals continues to lead in RNA interference (RNAi) therapeutics, with several approved siRNA drugs and a deep clinical pipeline. Alnylam’s bioinformatics-driven approach underpins its target selection and siRNA design, optimizing efficacy and safety profiles. In 2025, Alnylam is advancing partnerships with Regeneron Pharmaceuticals and Sanofi to co-develop RNAi therapies for rare and common diseases. These alliances combine Alnylam’s RNAi platform with partners’ disease expertise and global reach, facilitating rapid clinical development and commercialization (Alnylam Pharmaceuticals).

Moderna, renowned for its mRNA technology, is expanding its focus beyond vaccines to include mRNA-based therapeutics for rare diseases, oncology, and autoimmune disorders. Moderna’s proprietary bioinformatics and machine learning platforms are central to optimizing mRNA sequence design, delivery, and immunogenicity. In 2025, Moderna is deepening collaborations with Merck & Co., Inc. and AstraZeneca to co-develop mRNA therapeutics and personalized cancer vaccines, leveraging shared expertise in immunology and large-scale manufacturing (Moderna).

Other notable players include Sarepta Therapeutics, focusing on RNA-targeted therapies for neuromuscular diseases, and Arrowhead Pharmaceuticals, specializing in RNAi-based drugs for liver and cardiometabolic conditions. Both companies utilize advanced bioinformatics for target validation and oligonucleotide optimization, and are actively pursuing strategic partnerships to expand their pipelines and global reach.

Looking ahead, the sector is expected to see further consolidation and cross-disciplinary collaborations, as bioinformatics becomes increasingly integral to oligonucleotide drug development. The convergence of computational biology, genomics, and advanced delivery technologies is poised to accelerate the translation of oligonucleotide therapeutics from bench to bedside in the coming years.

AI and Machine Learning in Oligonucleotide Design and Optimization

The integration of artificial intelligence (AI) and machine learning (ML) into oligonucleotide design is rapidly transforming the landscape of bioinformatics-driven therapeutics as of 2025. These technologies are enabling unprecedented precision and efficiency in the identification, optimization, and validation of oligonucleotide drug candidates, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers.

Leading industry players are leveraging AI-powered platforms to accelerate the drug discovery process. Moderna, renowned for its mRNA technology, has expanded its computational capabilities to optimize sequence design, predict secondary structures, and minimize off-target effects. Their proprietary algorithms analyze vast datasets to enhance the stability and efficacy of oligonucleotide therapeutics. Similarly, Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapeutics, utilizes advanced bioinformatics and ML models to refine siRNA sequence selection, improving target specificity and reducing immunogenicity.

AI-driven platforms are also being developed by specialized bioinformatics companies. DNASTAR and GenScript offer cloud-based tools that employ ML algorithms for oligonucleotide design, secondary structure prediction, and off-target analysis. These platforms enable researchers to rapidly iterate and optimize candidate molecules, significantly shortening development timelines. Thermo Fisher Scientific provides integrated solutions that combine AI-based design with high-throughput synthesis and screening, supporting both academic and commercial R&D efforts.

Recent advances in deep learning are further enhancing the predictive power of these tools. Neural network models trained on large-scale experimental datasets can now forecast oligonucleotide efficacy, toxicity, and pharmacokinetics with increasing accuracy. This is particularly relevant for the design of next-generation therapeutics targeting rare or previously undruggable diseases. Companies such as Ionis Pharmaceuticals are investing in AI-driven analytics to expand their pipeline of ASO drugs, focusing on personalized medicine approaches.

Looking ahead, the next few years are expected to see even greater integration of AI and ML in oligonucleotide therapeutics. The convergence of multi-omics data, high-throughput screening, and real-world clinical outcomes will further refine predictive models, enabling the design of safer and more effective drugs. As regulatory agencies increasingly recognize the value of AI in drug development, industry leaders and technology providers are poised to set new standards for innovation and patient impact in the field of bioinformatics-driven oligonucleotide therapeutics.

Regulatory Environment and Industry Standards (e.g., fda.gov, ema.europa.eu)

The regulatory environment for bioinformatics-driven oligonucleotide therapeutics is rapidly evolving as these advanced modalities gain clinical and commercial traction. In 2025, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are intensifying their focus on the unique challenges and opportunities presented by oligonucleotide-based drugs, particularly those designed and optimized using bioinformatics and artificial intelligence.

Recent years have seen a surge in Investigational New Drug (IND) applications and marketing authorizations for antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and other nucleic acid-based therapeutics. Regulatory agencies are responding by updating guidance documents and establishing new frameworks to address the specificity, off-target effects, and manufacturing complexities inherent to these molecules. The FDA’s Center for Drug Evaluation and Research (CDER) has prioritized the development of regulatory science tools for nucleic acid therapeutics, including standards for sequence design, impurity profiling, and bioinformatics validation. The EMA, similarly, is collaborating with industry and academic stakeholders to harmonize requirements for oligonucleotide characterization, safety assessment, and data integrity.

A key regulatory trend in 2025 is the formal recognition of in silico bioinformatics tools as integral to the drug development process. Both the FDA and EMA now expect sponsors to provide comprehensive computational analyses of target selection, sequence optimization, and predicted off-target interactions as part of their regulatory submissions. This includes the use of machine learning algorithms to predict immunogenicity and toxicity, as well as the application of high-throughput screening data to support mechanism-of-action claims. The agencies are also encouraging the use of standardized data formats and interoperable software platforms to facilitate regulatory review and cross-study comparisons.

Industry standards are being shaped by leading oligonucleotide developers such as Ionis Pharmaceuticals, a pioneer in antisense technology, and Alnylam Pharmaceuticals, a leader in RNA interference therapeutics. These companies are actively engaging with regulators to define best practices for bioinformatics-driven design, quality control, and clinical translation. In parallel, organizations like the Biotechnology Innovation Organization (BIO) are facilitating pre-competitive collaborations to establish consensus standards for data sharing, sequence annotation, and digital traceability.

Looking ahead, the regulatory landscape is expected to become more adaptive, with agencies piloting real-time data monitoring and adaptive approval pathways for oligonucleotide therapeutics. The integration of bioinformatics into regulatory science will likely accelerate the approval of personalized and rare disease-targeted oligonucleotide drugs, while ensuring robust safety and efficacy standards. As the field matures, ongoing dialogue between regulators, industry, and technology providers will be critical to maintaining public trust and fostering innovation.

Emerging Therapeutic Applications: Rare Diseases, Oncology, and Beyond

Bioinformatics-driven oligonucleotide therapeutics are rapidly transforming the landscape of drug development, particularly in the treatment of rare diseases, oncology, and other challenging indications. The integration of advanced computational tools with oligonucleotide design is enabling the precise targeting of genetic mutations and regulatory elements, accelerating the path from discovery to clinical application.

In 2025, the field is witnessing a surge in the number of oligonucleotide-based therapies entering clinical trials, with a significant proportion focused on rare genetic disorders. Companies such as Ionis Pharmaceuticals and Alnylam Pharmaceuticals are at the forefront, leveraging proprietary bioinformatics platforms to design antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that modulate gene expression with high specificity. For example, Ionis Pharmaceuticals continues to expand its pipeline of ASOs for neuromuscular and metabolic diseases, while Alnylam Pharmaceuticals is advancing siRNA therapeutics for rare and ultra-rare conditions, including hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria.

In oncology, bioinformatics is enabling the identification of novel RNA targets and the rational design of oligonucleotides that can overcome resistance mechanisms or target undruggable genes. Moderna, known for its mRNA technology, is expanding into oligonucleotide therapeutics for cancer, utilizing machine learning algorithms to optimize sequence selection and delivery. Similarly, Sarepta Therapeutics is applying advanced analytics to develop exon-skipping oligonucleotides for rare cancers and muscular dystrophies.

Beyond rare diseases and oncology, bioinformatics-driven approaches are being applied to infectious diseases, cardiovascular disorders, and even personalized medicine. The use of high-throughput sequencing data and AI-powered target prediction is enabling companies like Biogen and Roche to expand their oligonucleotide portfolios into new therapeutic areas. These companies are investing in in silico screening and predictive modeling to reduce off-target effects and improve the safety profiles of their candidates.

Looking ahead, the next few years are expected to bring further integration of multi-omics data, real-world evidence, and patient-specific genomics into oligonucleotide drug design. This will likely result in more personalized and effective therapies, faster development timelines, and expanded indications. As regulatory agencies adapt to these innovations, the approval and commercialization of bioinformatics-driven oligonucleotide therapeutics are poised to accelerate, offering hope for patients with previously untreatable conditions.

Manufacturing Advances and Supply Chain Dynamics

The manufacturing landscape for bioinformatics-driven oligonucleotide therapeutics is undergoing rapid transformation in 2025, propelled by both technological innovation and evolving supply chain strategies. The integration of advanced bioinformatics tools has enabled the design of highly specific oligonucleotide sequences, accelerating the transition from in silico discovery to scalable production. This shift is particularly evident in the synthesis of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and other nucleic acid-based modalities, where precision and purity are paramount.

Key industry players are investing heavily in automated, high-throughput synthesis platforms. Thermo Fisher Scientific has expanded its oligonucleotide manufacturing capabilities, leveraging robotics and digital process controls to ensure batch consistency and reduce turnaround times. Similarly, Agilent Technologies continues to refine its solid-phase synthesis technologies, focusing on scalability and the minimization of impurities, which is critical for clinical-grade oligonucleotides.

Supply chain resilience has become a central concern, especially in the wake of recent global disruptions. Companies such as Integrated DNA Technologies (IDT), a subsidiary of Danaher, are diversifying their raw material sourcing and establishing regional manufacturing hubs to mitigate risks associated with single-source dependencies. This decentralization is complemented by digital supply chain management systems, which use real-time data analytics to forecast demand and optimize inventory levels.

Another significant trend is the adoption of green chemistry principles in oligonucleotide manufacturing. Eurofins Scientific and LGC Group are piloting solvent recycling and waste minimization protocols, aiming to reduce the environmental footprint of large-scale synthesis. These initiatives are increasingly important as regulatory agencies and biopharma partners prioritize sustainability in their procurement criteria.

Looking ahead, the next few years are expected to see further convergence between bioinformatics and manufacturing. Artificial intelligence-driven sequence optimization is anticipated to streamline not only the design but also the manufacturability of oligonucleotides, reducing failure rates and improving yields. Strategic partnerships between bioinformatics firms and contract development and manufacturing organizations (CDMOs) are likely to proliferate, as seen in recent collaborations involving Lonza, which is expanding its nucleic acid production services to meet growing demand for personalized and rare disease therapeutics.

In summary, the manufacturing and supply chain ecosystem for bioinformatics-driven oligonucleotide therapeutics in 2025 is characterized by automation, digitalization, sustainability, and strategic risk management. These advances are poised to support the sector’s continued growth and its ability to deliver innovative therapies at scale.

Market Growth Projections: CAGR of 14–17% Through 2030

The market for bioinformatics-driven oligonucleotide therapeutics is poised for robust expansion, with projections indicating a compound annual growth rate (CAGR) of approximately 14–17% through 2030. This surge is underpinned by the convergence of advanced bioinformatics tools and the increasing clinical validation of oligonucleotide-based drugs, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers. The integration of bioinformatics accelerates target identification, optimizes sequence design, and enhances off-target prediction, thereby reducing development timelines and costs.

Key industry players are investing heavily in both proprietary bioinformatics platforms and strategic collaborations. Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapeutics, continues to expand its pipeline by leveraging computational biology for target discovery and siRNA optimization. Similarly, Ionis Pharmaceuticals utilizes advanced informatics to design next-generation ASOs, with several candidates progressing through late-stage clinical trials. Sarepta Therapeutics is also notable for its use of bioinformatics in the development of exon-skipping oligonucleotides for rare neuromuscular diseases.

The market’s growth is further catalyzed by the increasing number of regulatory approvals and the expansion of therapeutic indications. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved multiple oligonucleotide drugs in recent years, validating the clinical potential of these modalities. This regulatory momentum is expected to continue, with a growing number of candidates in late-stage pipelines, particularly for rare genetic disorders and oncology.

Geographically, North America and Europe remain the dominant markets, driven by strong R&D infrastructure and supportive regulatory frameworks. However, Asia-Pacific is emerging as a significant growth region, with companies such as Nitto Denko Corporation and Samsung Biologics investing in oligonucleotide manufacturing and development capabilities.

Looking ahead to 2025 and beyond, the market outlook remains highly favorable. The continued evolution of artificial intelligence and machine learning in bioinformatics is expected to further streamline oligonucleotide drug discovery and development. As more personalized and precision medicine approaches gain traction, the demand for bioinformatics-driven oligonucleotide therapeutics is set to accelerate, supporting sustained double-digit market growth through the end of the decade.

Future Outlook: Challenges, Opportunities, and Next-Gen Technologies

The future of bioinformatics-driven oligonucleotide therapeutics is poised for significant transformation as the field leverages advances in computational biology, artificial intelligence (AI), and high-throughput screening. As of 2025, the integration of multi-omics data and machine learning is accelerating the identification and optimization of oligonucleotide drug candidates, with several industry leaders and emerging biotech firms at the forefront.

One of the primary challenges remains the accurate prediction of off-target effects and immunogenicity. Companies such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals are investing in proprietary bioinformatics platforms to refine sequence selection and chemical modification, aiming to enhance specificity and reduce adverse events. These platforms utilize large datasets from clinical and preclinical studies, feeding into AI models that can predict molecular interactions and patient responses with increasing precision.

Opportunities are expanding as next-generation sequencing (NGS) and single-cell analysis become more accessible, enabling the discovery of novel RNA targets and the development of personalized oligonucleotide therapies. Moderna and Sarepta Therapeutics are notable for their investments in data-driven approaches to design and optimize antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) for rare and common diseases. These companies are also exploring the use of cloud-based bioinformatics infrastructure to facilitate global collaboration and accelerate the drug development pipeline.

Looking ahead, the next few years are expected to see the emergence of AI-powered platforms capable of de novo oligonucleotide design, integrating structural modeling, real-world patient data, and predictive toxicology. Roche and Novartis are actively developing such platforms, aiming to shorten the timeline from target discovery to clinical candidate selection. Additionally, the adoption of CRISPR-based screening and high-content phenotypic assays is anticipated to further refine target validation and functional genomics, supporting the rational design of oligonucleotide drugs.

Despite these advances, regulatory and manufacturing challenges persist, particularly regarding the standardization of bioinformatics pipelines and the scalability of oligonucleotide synthesis. Industry consortia and regulatory bodies are expected to issue new guidelines in the coming years to address data integrity, reproducibility, and quality control in bioinformatics-driven drug development. As the sector matures, collaborations between pharmaceutical companies, technology providers, and academic institutions will be critical to overcoming these hurdles and unlocking the full therapeutic potential of oligonucleotide medicines.

Sources & References

• Alnylam Pharmaceuticals
• Biogen
• QIAGEN
• Alnylam Pharmaceuticals
• Thermo Fisher Scientific
• Roche
• Thermo Fisher Scientific
• Novartis
• Roche
• Regeneron Pharmaceuticals
• Merck & Co., Inc.
• Sarepta Therapeutics
• Arrowhead Pharmaceuticals
• European Medicines Agency
• Biotechnology Innovation Organization
• Sarepta Therapeutics
• Integrated DNA Technologies
• LGC Group
• Samsung Biologics